Story behind meldonium–from pharmacology to performance enhancement: a narrative review
The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Recent reports from the World Anti-Doping Agency (WADA) indicate an alarming prevalence in the use of meldonium among elite athletes. Therefore, in January 2016, meldonium was added to WADA's prohibited list after being monitored since 2015. Meldonium has been shown to have beneficial effects in cardiovascular, neurological and metabolic diseases due to its anti-ischaemic and cardioprotective properties, which are ascribed mainly to its inhibition of ß-oxidation and its activation of glycolysis. Despite its widespread use, there are only a few clinical studies or clinical trials available. Meldonium is registered in most Baltic countries and is easily accessible through the internet with no serious adverse effects reported by the manufacturer so far. Among athletes, meldonium is used with the purpose of increasing recovery rate or exercise performance. The benefit of taking meldonium in view of performance enhancement in athletes is quite speculative and is discussed without sound scientific evidence. This narrative review provides a detailed overview of the drug meldonium, focusing on the main topics pharmacology and biochemical actions, clinical applications, pharmacokinetics, methods of detection and potential for performance enhancement in athletes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We can note only two works published in English re- garding the possible ability of meldonium to enhance athletic performance, one of which is a narrative review (28,29).”
From The Inclusion in WADA Prohibited List Is Not Always Supported by Scientific Evidence: A Narrative Review (2021) · cites this paper as [29]
Citations
Cites
Anderson, E. J., Lustig, M. E., Boyle, K. E., Woodlief, T. L., Kane, D. A., Lin, C.-T., Price, J. W., Kang, L., Rabinovitch, P. S., Szeto, H. H., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37048 · Cited by 1,253
Carnitine biosynthesis in mammals
Vaz, F. M., & Wanders, R. J. A. (2002) · Biochemical Journal · doi:10.1042/0264-6021:3610417 · Cited by 764
Skeletal Muscle Lipid Metabolism in Exercise and Insulin Resistance
Kiens, B. (2006) · Physiological Reviews · doi:10.1152/physrev.00023.2004 · Cited by 478
Kinetics, Pharmacokinetics, and Regulation of l‐Carnitine and Acetyl‐l‐carnitine Metabolism
REBOUCHE, C. J. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1320.003 · Cited by 425
Relationship between fatty acid delivery and fatty acid oxidation during strenuous exercise
Romijn, J. A., Coyle, E. F., Sidossis, L. S., Zhang, X. J., & Wolfe, R. R. (1995) · Journal of Applied Physiology · doi:10.1152/jappl.1995.79.6.1939 · Cited by 248
Ribas, G. S., Vargas, C. R., & Wajner, M. (2014) · Gene · doi:10.1016/j.gene.2013.10.017 · Cited by 246
Acylcarnitines: potential implications for skeletal muscle insulin resistance
Aguer, C., McCoin, C. S., Knotts, T. A., Thrush, A. B., Ono‐Moore, K., McPherson, R., Dent, R., Hwang, D. H., Adams, S. H., & Harper, M. (2015) · The FASEB Journal · doi:10.1096/fj.14-255901 · Cited by 240
Wanders, R. J. A., Vreken, P., Ferdinandusse, S., Jansen, G. A., Waterham, H. R., van Roermund, C. W. T., & Van Grunsven, E. G. (2001) · Biochemical Society Transactions · doi:10.1042/bst0290250 · Cited by 225
Wall, B. T., Stephens, F. B., Constantin‐Teodosiu, D., Marimuthu, K., Macdonald, I. A., & Greenhaff, P. L. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2010.201343 · Cited by 175
Enzymology of the carnitine biosynthesis pathway
Strijbis, K., Vaz, F. M., & Distel, B. (2010) · IUBMB Life · doi:10.1002/iub.323 · Cited by 154
Research works printed but not linked: 4
- 10.1042/bj3610417 · DOI · Paper page
- Heidemanis, 1990, Mildronate-plasma membrane interaction mechanisms, Proc Latv Acad Sci, 11, 108
- Dzerve, 2005, Mildronate improves peripheral circulation in patients with chronic heart failure: results of clinical trial (the first report), Sem Cardiol, 11, 56
- Kakhabrishvili, 2002, Effect of Mildronate on physical working capacity of highly qualified judoka, Ann Biomed Res Educ Tbilisi State Med Univ, 2, 263
Cited by
Bezuglov, E., Talibov, O., Butovskiy, M., Khaitin, V., Achkasov, E., Waśkiewicz, Z., & Lazarev, A. (2021) · Asian Journal of Sports Medicine · doi:10.5812/asjsm.110753 · Cited by 26
Rabin, O., Uiba, V., Miroshnikova, Y., Zabelin, M., Samoylov, A., Karkischenko, V., Semyonov, S., Astrelina, T., & Razinkin, S. (2019) · Drug Testing and Analysis · doi:10.1002/dta.2521 · Cited by 26
Metadata
- Authors
- Schobersberger, W., Dünnwald, T., Gmeiner, G., & Blank, C.
- Affiliations
- UMIT TIROL - Private University for Health Sciences and Health Technology (AT)
- Seibersdorf Laboratories (Austria) (AT)
- Corresponding author
- Schobersberger, Wolfgang
- Venue
- British Journal of Sports Medicine
- Publisher
- BMJ
- Published
- 2016-07-27
- Volume
- 51
- Issue
- 1
- Pages
- 22-25
- ISSN
- 0306-3674 (ISSN-L)
- 1473-0480
- OpenAlex
- W2494230548
- Cited by
- 61
- References
- 68
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 9 · 2023: 5 · 2022: 9 · 2021: 5 · 2020: 4 · 2019: 5 · 2018: 6 · 2017: 5 · 2016: 2
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- British Journal of Sports Medicine (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Social Sciences › Sociology and Political Science › Doping in Sports
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Pharmacological Effects and Assays
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Sports Performance and Training
- Keywords
- meldonium, anti-doping, performance-enhancing drugs, athletes, pharmacology, pharmacokinetics, drug detection, beta-oxidation inhibition, cardioprotection, anti-ischemic effect
- MeSH terms
- Cardiovascular Diseases, Carnitine, Doping in Sports, Humans, Metabolic Diseases, Methylhydrazines, Nervous System Diseases, Athletic Performance, Athletes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Story behind meldonium–from pharmacology to performance enhancement: a narrative review. https://app.cochat.ai/papers/10.1136/bjsports-2016-096357
- The paper
- Schobersberger, W., Dünnwald, T., Gmeiner, G., & Blank, C. (2017). Story behind meldonium–from pharmacology to performance enhancement: a narrative review. British Journal of Sports Medicine. https://doi.org/10.1136/bjsports-2016-096357
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.